Acadia Pharmaceuticals Inc. (ACAD)

[IanFromSI]

Acadia rises as FDA posts briefing docs ahead of AdCom meeting on antipsychotic therapy
The shares of the commercial-stage biotech Acadia Pharmaceuticals (NASDAQ:ACAD) surged ~29% in the Wednesday after the FDA published briefing documents on antipsychotic therapy pimavanserin targeted at patients with Alzheimer’s disease.
A group of independent experts advising the agency are set to meet on Friday to discuss the approvability of the drug as a treatment for hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).
The FDA's advisory committees issue non-binding recommendations. However, the regulator usually follows them before making a final decision on authorizations.
Pimavanserin is currently marketed as Nuplazid for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
The FDA has assigned an action date for August 04 to review the marketing application for the new indication.